Kirin (United States)

Recent papers from Kirin (United States)

1. Real-World Effectiveness of Burosumab Versus Oral Phosphate and Active Vitamin D in Adults with X-Linked Hypophosphatemia (XLH): A 3-Year Follow-Up of the XLH Disease Monitoring ProgramJournal of Bone and Mineral Research · 2026
2. ATRX inactivation disrupts global chromatin state and topology to dysregulate neurodevelopmental pathways in glioma pathogenesisNucleic Acids Research · 2026
3. Safety, tolerability, pharmacokinetics, and efficacy of burosumab in infants with X-linked hypophosphataemia: an open-label, multicentre, non-randomised studyThe Lancet Diabetes & Endocrinology · 2026
4. Real-world monotherapy and combination usage of mogamulizumab among patients with mycosis fungoides or Sézary syndrome in the United StatesBlood · 2025
5. First‐in‐human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumorsCancer · 2025
6. The dawn of a new era: can machine learning and large language models reshape QSP modeling?Journal of Pharmacokinetics and Pharmacodynamics · 2025
7. Real-world effectiveness of burosumab vs oral phosphate and active vitamin D in adults with X-linked hypophosphatemiaJournal of Bone and Mineral Research · 2025
8. Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumabJournal of Dermatological Treatment · 2025
9. Comparative Safety of Istradefylline Among Parkinson Disease Adjunctive Therapies: A Systematic Review and Meta-analysis of Randomized Controlled StudiesClinical Neuropharmacology · 2025
10. Semisynthesis of bersavine and berbamine derivatives that target the CaMKIIγ:cMyc axis for lymphoma therapyOrganic & Biomolecular Chemistry · 2025
11. Durable improvements in atopic dermatitis in the head and neck and across other anatomic regions with rocatinlimabArchives of Dermatological Research · 2024
12. Real-World Clinical and Healthcare Resource Burden Among Burosumab-Naïve Patients With Familial HypophosphatemiaJournal of the Endocrine Society · 2024
13. Model‐Informed Approach to Recommend Burosumab Dosing Regimens for Pediatric and Adult Patients With the Ultrarare Disease Tumor‐Induced OsteomalaciaClinical Pharmacology & Therapeutics · 2024
14. Content Evaluation of Pruritus, Skin Pain, and Sleep Disturbance Patient-Reported Outcome Measures in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: Qualitative InterviewsBritish Journal of Dermatology · 2024
15. Pharmacodynamic Exposure–Response Analysis of Fracture Count Data Following Treatment with Burosumab in Patients with XLHThe Journal of Clinical Pharmacology · 2024
16. A Retrospective Cohort Study to Determine Real-World Treatment Patterns in Patients with Sézary Syndrome in the United StatesOncology and Therapy · 2024
17. Item Response Theory Quantifies the Relationship Between Improvements in Serum Phosphate and Patient‐Reported Outcomes in Adults With X‐Linked HypophosphatemiaClinical Pharmacology & Therapeutics · 2024
18. Population Pharmacokinetics of Naloxegol in Pediatric Subjects Receiving OpioidsClinical Pharmacology in Drug Development · 2024
19. 679 - Rocatinlimab significantly improves clinical responses in patients with moderate-to-severe atopic dermatitis by week 2 in a randomized double-blind placebo-controlled phase 2b studyBritish Journal of Dermatology · 2024
20. Association between work productivity and characteristics of adults with X-linked hypophosphatemia: an analysis of the XLH disease monitoring programJBMR Plus · 2024